Infliximab May Impede Serologic Response to SARS-CoV-2
Concomitant immunomodulator use further blunted antibody responses to SARS-CoV-2 among infliximab-treated IBD patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.